The metabolic pathways that replenish TCA cycle intermediates — exploring disorders, therapies, and the frontier of anaplerotic medicine.
Health Information Contributors
Content is authored and reviewed by contributors with interest in genetics and health information. Content is for informational purposes only.
The TCA cycle is the metabolic crossroads of every cell. When anaplerotic pathways fail—due to inherited enzyme deficiencies in pyruvate carboxylase, propionyl-CoA carboxylase, or fatty acid oxidation enzymes—the clinical consequences are devastating: metabolic crises, cardiomyopathy, neurodegeneration, and sudden death in infancy.
The 2020 FDA approval of triheptanoin (Dojolvi®) marked the first therapy explicitly designed around anaplerotic biochemistry. This site tracks the science behind that breakthrough and the expanding frontier of anaplerotic medicine—from Huntington disease to refractory epilepsy to cancer immunometabolism.
Content on this site references publicly available scientific literature and is provided for informational purposes only. It does not constitute medical advice.
This site is intended for educational purposes. It does not replace professional medical advice, diagnosis, or treatment.
For editorial inquiries, corrections, or domain acquisition interest: Get in touch →